Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
Clinical
Norman Boyd, MD, DSC
Ontario Cancer Institute
Toronto, CANADA
Biological basis of breast density and cancer risk
Thea D. Tlsty, PhD
University of California, San Francisco
San Francisco, CA
3:15 pm–5:00 pm
GENERAL SESSION 4
Exhibit Hall D
Moderator: Matthew Goetz, MD
Mayo Clinic College of Medicine
Rochester, MN
3:15 S4-1. The UK START (Standardisation of Breast Radiotherapy)
Trials: 10-Year follow-up results
Haviland JS, Agrawal R, Aird E, Barrett J, Barrett-Lee P, Brown J, Dewar J,
Dobbs J, Hopwood P, Hoskin P, Lawton P, Magee B, Mills J, Morgan D,
Owen R, Simmons S, Sydenham M, Venables K, Bliss JM, Yarnold JR, on
behalf of the START Trialists. The Institute of Cancer Research, Sutton,
United Kingdom; Shrewsbury and Telford Hospital NHS Trust, United
Kingdom; Mount Vernon Hospital, Northwood, United Kingdom; Royal
Berkshire NHS Foundation Trust, Reading, United Kingdom; Velindre
Hospital NHS Trust, Cardiff, United Kingdom; previously University of
Bristol, now Eli Lilly & Company, United Kingdom; formerly Ninewells
Hospital, Dundee, United Kingdom; formerly Guys and St Thomas’
NHS Trust, London, United Kingdom; Nottingham City Hospital, United
Kingdom; formerly The Christie NHS Foundation Trust, Manchester,
United Kingdom; formerly Nottingham University Hospital NHS Trust,
United Kingdom; formerly Cheltenham General Hospital, United
Kingdom; The Institute of Cancer Research and Royal Marsden NHS
Foundation Trust, Sutton, United Kingdom.
3:30 S4-2. Targeted intraoperative radiotherapy for early breast cancer:
TARGIT-A trial- updated analysis of local recurrence and first
analysis of survival
Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M, Flyger
H, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M,
Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson
A, Dewar JA, Holtveg H, Pigorsch S, Falzon M, Harris E, Matthews A,
Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. University
College London, London, United Kingdom; University Medical Centre
Mannheim, University of Heidelberg, Heidelberg, Germany; University of
Notre Dame, Fremantle, Australia; Sir Charles Gairdner Hospital, Perth,
Australia; University College Hospital, London, United Kingdom; Royal
Free Hospital, London, United Kingdom; University of Copenhagen,
Copenhagen, Denmark; Centro di Riferimento Oncologia, Aviano, Italy;
University of California, San Francisco, CA; University of Western Australia,
Perth, WA, Australia; Red Cross Hospital, Munich, Germany; Ninewells
Hospital, Dundee, United Kingdom; Technical University of Munich,
Munich, Germany; University College London Hospitals, London, United
Kingdom; National Cancer Research Institute and Independent Cancer
Patient’s, Voice, United Kingdom; Moffit Cancer Centre , Tampa, FL.
3:45 S4-3. The EndoPredict score identifies late distant metastases in
ER+/HER2- breast cancer patients
Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber
KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M, Filipits M.
Medical University Vienna, Austria; Sividon Diagnostics GmbH, Cologne,
Germany; Paracelsus Private Medical University, Salzburg, Austria; Sisters
of Charity Hospital, Linz, Austria.
4:00 S4-4. Independent validation of Genomic Grade in the
BIG 1-98 study
Sotiriou C, Ignatiadis M, Desmedt C, Azim Jr. HA, Veys I, Larsimont D,
Lyng M, Viale G, Leyland-Jones B, Ditzel H, Giobbie-Hurder A, Regan M,
Piccart M, Michiels S. Universite Libre de Bruxelles; Institut Jules Bordet;
University of Southern Denmark; University of Milan; Edith Sanford
Research; Harvard Medical School.
4:15 S4-5. Ki67 levels in pretherapeutic core biopsies as predictive and
prognostic parameters in the neoadjuvant GeparTrio trial
Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber
B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler
J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G. Charite
University Hospital, Berlin, Germany; Sankt Gertrauden Krankenhaus,
Berlin, Germany; Christian-Albrechts Universität zu Kiel, Kiel, Germany;
Rotkreuzklinikum, München, Germany; Universitätsfrauenklinik Rostock,
Germany; Bethanien Krankenhaus, Frankfurt, Germany; Eilenriede Klinik,
Hannover, Germany; University of Düsseldorf, Germany; Universitäts
Frauenklinik, Tübingen, Germany; Kliniken Essen Mitte, Essen, Germany;
Klinikum Offenbach, Offenbach, Germany; Klinikum Karlsruhe, Karlsruhe,
Germany; Klinikum St. Salvator, Halberstadt, Germany; German Breast
Group, Neu-Isenburg, Germany.
4:30 S4-6. An international Ki67 reproducibility study
Nielsen TO, Polley M-YC, Leung SCY, Mastropasqua MG, Zabaglo LA,
Bartlett JMS, Viale G, McShane LM, Hayes DF, Dowsett M, on behalf of
the International Ki67 in Breast Cancer Working Group of the BIG-NABCG
collaboration. University of British Columbia, Vancouver, BC, Canada;
National Cancer Institute, Bethesda, MD; European Institute of Oncology,
Milan, Italy; The Institute of Cancer Research, London, United Kingdom;
Ontario Institute for Cancer Research, Toronto, ON, Canada; University of
Michigan Comprehensive Cancer Center, Ann Arbor, MI; Royal Marsden
Hospital, London, United Kingdom; Breast International Group-North
American Breast Cancer Group Collaboration.
4:45 S4-7. Discussion
W. Fraser Symmans, MD, MD Anderson Cancer Center, Houston, TX
5:00 pm–7:00 pm
Poster Discussion 5: Clinical Sequencing
Ballroom A
Viewing 5:00 pm
Discussion 5:15 pm
Charles Perou, PhD, Chair
University of North Carolina
Chapel Hill, NC
Katherine Hoadley, PhD, Discussant
University of North Carolina
Chapel Hill, NC
and
Christine Desmedt, PhD, Discussant
Jules Bordet Institute
Bruxelles, BELGIUM
PD05-01 Next generation genomic sequencing (NGS) identifies
molecular targets in inflammatory breast cancer (IBC)
Cristofanilli M, Alpaugh KR, Ross J, Binghman C, Wu H, Stephens
P, Lipson D, Palmer G. Fox Chase Cancer Center, Philadelphia, PA;
Foundation Medicine, Cambridge, MA.
PD05-02 Novel mutations in lobular carcinoma in situ (LCIS) as
uncovered by targeted parallel sequencing
De Brot M, Andrade VP, Morrogh M, Berger MF, Won HH, Koslow
Mautner S, Qin L-X, Giri DD, Olvera N, Sakr RA, King TA. Memorial
Sloan-Kettering Cancer Center, New York, NY.
PD05-03 What is the appropriate sample (s) on which to perform
sequencing for mutational analysis to guide the selection of
targeted therapy?
Alpaugh RK, Bingham C, Fittipaldi P, Banzi M, Palmer G, Cristofanilli
M. Fox Chase Cancer Center, Philadelphia, PA; Silicon Biosystems,
Spa, Bologna, Italy; Foundation Medicine, Cambridge, MA.
PD05-04 Targeted resequencing in oncogenetics : developing a new
approach for molecular diagnostics
Sevenet N, Lafon D, Dupiot-Chiron J, Hubert C, Jones N, Debled M,
Tunon de Lara C, Longy M, Bonnet F. Institut Bergonie, Bordeaux,
France; Centre de Génomique Foncionnelle de Bordeaux, Bordeaux,
France; Institut Bergonie & Universite Bordeaux Segalen, Bordeaux,
France.
Cancer Res; 72(24 Suppl.) December 15, 2012 32s Cancer Research